Biosimilar Trends: What 2017 May Have In Store
Executive Summary
Potential approvals for biosimilar versions of three blockbuster products in the EU and/or the US in 2017, growing prescriber confidence in such products against the backdrop of positive switching studies, and early signs of market consolidation were some of the key trends highlighted at a recent roundtable in Mumbai.
You may also be interested in...
First Biosimilar MabThera One Step Away from EU Approval; Pegfilgrastim Filings Withdrawn
The CHMP has granted a positive opinion to Celltrion’s Truxima, the first biosimilar version of Roche’s cancer treatment, MabThera, but has announced the withdrawal of two pegfilgrastim products.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.